The translocator protein 18kDa ligand etifoxine in the treatment of depressive disorders—a double-blind, randomized, placebo-controlled proof-of-concept study

Abstract Background Recent developments suggest that neurosteroids may achieve rapid antidepressant effects. As such, neurosteroidogenesis mediated by the translocator protein 18 kDa (TSPO) might constitute a promising option for the treatment of depression. Therefore, the current clinical trial aim...

Полное описание

Библиографические подробности

Главные авторы:	Lisa-Marie Brunner, Marco Riebel, Simon Wein, Michael Koller, Florian Zeman, Gunnar Huppertz, Tanja Emmer, Yvonne Eberhardt, Jens Schwarzbach, Rainer Rupprecht, Caroline Nothdurfter
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMC 2024-04-01
Серии:	Trials
Предметы:	Randomized controlled trial TSPO Etifoxine Depression Neurosteroids Functional MRI
Online-ссылка:	https://doi.org/10.1186/s13063-024-08120-x
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!